Specialist education programs on responsible prescribing of expensive drugs such as bDMARDs will continue after NPS MedicineWise shuts its doors at the end of this year, the service has confirmed.
The NPS formally announced last week it was ceasing all operations on 31 December and would also legally wind up from that date.
It follows the Federal Government’s decision to end its $25 million in annual taxpayer funding – which had been the overwhelming majority of NPS’ budget.
In an update on Friday, it said most of its activities – including Value in Prescribing, Choosing Wisely, the MedicineInsight dataset – will move the government-owned Australian Commission on Safety and Quality in Health Care (ACSQHC), which is also taking over the service’s website.
The commission will also be taking over the PBS/MBS practice reviews, which are regularly mailed to GPs on their prescribing or test ordering, but have also been prepared for specialists in recent years.
As part of the ‘Value in Prescribing’ program, annual letters were sent to 450 rheumatologists until May this year analysing their prescribing of biological disease modifying anti-rheumatic drugs (bDMARDS) as well as glucocorticoids and opioids.
Created with government grant money totalling more than $9.2 million, each review featured an individualised comparison of the recipient’s prescribing with the national average across 2019, 2020 and 2021.